RS51227B - Makrociklički inhibitori virusa hepatitisa c - Google Patents

Makrociklički inhibitori virusa hepatitisa c

Info

Publication number
RS51227B
RS51227B RSP-2010/0183A RSP20100183A RS51227B RS 51227 B RS51227 B RS 51227B RS P20100183 A RSP20100183 A RS P20100183A RS 51227 B RS51227 B RS 51227B
Authority
RS
Serbia
Prior art keywords
c6alkyl
independently
c3alkylene
c6alkoxy
alkylenecarbocyclyl
Prior art date
Application number
RSP-2010/0183A
Other languages
English (en)
Inventor
Herman Augustinus De Kock
Lili Hu
Kenneth Alan Simmen
Karin Charlotta Lindquist
Mats Stefan LINDSTRÖM
Anna Karin Gertrud Linnea Belfrage
Horst Jürgen WÄHLING
Karl Magnus Nilsson
Bengt Bertil Samuelsson
Aasa Annica Kristina Rosenquist
Sven Crister Sahlberg
Hans Kristian Wallberg
Pia Cecilia Kahnberg
Björn Olof CLASSON
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Tibotec Pharmaceuticals
Medivir Ab.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51227(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharmaceuticals, Medivir Ab. filed Critical Tibotec Pharmaceuticals
Publication of RS51227B publication Critical patent/RS51227B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D245/00Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Jedinjenje formule I:i N-oksidi, soli i stereoizomeri od toga, naznačeno time da: A je OR1, NHS(=O)pR2; u čemu;R1 je vodonik, C1-C6alkil, C0-C3alkilenkarbociklil. C0-C3alkilenheterociklil; R2 je C1-C6alkil, C0-C3alkilenkarbociklil C0-C3alkilenheterociklil; p je nezavisno 1 ili 2; n je 3, 4, 5 ili 6;-----označava dvostruku vezu po izboru;L je N ili CRz;Rz je H ili formira dvostruku vezu sa ugljenikom obeleženim asteriskom; Rq je H ili kada L je CRz, Rq može također da bude C1-C6alkil;Rr je kvinazolinil, po izboru supstituisan sa jednim, dva ili tri supstituenta, vaki nezavisno izabran između C1-C6alkil, C1-C6alkoksi. hidroksil, halo, haloC1-C6alkil, amino, mono- ili dialkilamino, mono- ili dialkilaminokarboni1, C1-C6alkilkarbonilamino, C0-C3alkilenkarbociklil i C0-C3 alkilenheterociklil;R5 je vodonik, C1-C6alkil, C1-C6alkoksiC1-C6alkiL ili C3-C7cikloalkil; i u čemusvaki C1-C6alkil, C0-C3alkilenkarbocikil ili C0-C3alkilenheterociklil je po izboru supstituisan sa 1 do 3 supstituenta nezavisno izabrana iz grupe koja se sastoji od halo, okso, nitril, azido, nitro, C1-C6alkil, C0-C3alkilenkarbociklil, C0-C3alkilen-heterociklil, NH2C(=O)-, Y-NRaRb, Y-O-Rb, Y-C(=O)Rb, Y-(C=O)NRaRb, Y-NRaC(=O)Rb. Y-NHS(=Op)Rb. Y-S(=O)pRb i Y-S(=O)pNRaRb, Y-C(=O)ORb, Y-NRaC(=O)ORb;Y je nezavisno veza ili C1-C3alkilen; Ra je nezavisno H, C1-C6alkoksi, C1-C3alkil ili:Rb je nezavisno H, C1-C6alkil, C1-C6alkoksi. C0-C3alkilen-karbociklil ili C0-C3alkilenheterociklil;ili Ra i Rb zajedno sa azotom na kojeg su vezani formiraju heterociklilnu grupu.Prijava sadrži još 27 zavisnih patentnih zahteva.
RSP-2010/0183A 2005-07-29 2006-07-28 Makrociklički inhibitori virusa hepatitisa c RS51227B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05107057 2005-07-29
EP06113097 2006-04-25
PCT/EP2006/064822 WO2007014927A2 (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
RS51227B true RS51227B (sr) 2010-12-31

Family

ID=37708968

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2010/0183A RS51227B (sr) 2005-07-29 2006-07-28 Makrociklički inhibitori virusa hepatitisa c

Country Status (32)

Country Link
US (1) US7659245B2 (sr)
EP (1) EP1912981B1 (sr)
JP (1) JP5230418B2 (sr)
KR (1) KR101083631B1 (sr)
AP (1) AP2585A (sr)
AR (1) AR057702A1 (sr)
AT (1) ATE455775T1 (sr)
AU (1) AU2006274866B2 (sr)
BR (1) BRPI0614153A2 (sr)
CA (1) CA2617103C (sr)
CY (1) CY1110008T1 (sr)
DE (1) DE602006011905D1 (sr)
DK (1) DK1912981T3 (sr)
EA (1) EA014188B1 (sr)
ES (1) ES2339702T3 (sr)
GT (1) GT200600343A (sr)
HK (1) HK1116488A1 (sr)
HR (1) HRP20100209T1 (sr)
IL (1) IL188320A (sr)
ME (1) ME01454B (sr)
MY (1) MY151026A (sr)
NO (1) NO20081075L (sr)
NZ (1) NZ564540A (sr)
PE (1) PE20070343A1 (sr)
PL (1) PL1912981T3 (sr)
PT (1) PT1912981E (sr)
RS (1) RS51227B (sr)
SI (1) SI1912981T1 (sr)
SV (1) SV2008002641A (sr)
TW (1) TWI387597B (sr)
UY (1) UY29704A1 (sr)
WO (1) WO2007014927A2 (sr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
ATE461209T1 (de) 2004-01-30 2010-04-15 Medivir Ab Hcv ns-3 serine protease inhibitoren
WO2007014925A1 (en) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis c virus
AR057704A1 (es) 2005-07-29 2007-12-12 Tibotec Pharm Ltd Inhibidores macrociclicos del virus de la hepatitis c, composicion farmaceutica y proceso de preparacion del compuesto
JO2768B1 (en) * 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
GEP20104956B (en) 2005-10-11 2010-04-12 Array Biopharma Inc Compounds for inhibiting hepatitis c viral replication and use thereof
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. C형 간염 바이러스 복제의 신규 억제제
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906619B2 (en) 2006-07-13 2011-03-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20090079881A (ko) * 2006-11-17 2009-07-22 티보텍 파마슈티칼즈 리미티드 C형 간염 바이러스의 마크로사이클릭 억제제
US8212043B2 (en) * 2007-02-01 2012-07-03 Janssen R&D Ireland Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV
CN101641349A (zh) * 2007-02-08 2010-02-03 泰博特克药品有限公司 嘧啶取代的大环抑制剂
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
WO2009042668A2 (en) * 2007-09-24 2009-04-02 Achillion Pharmaceuticals, Inc. Urea-containing peptides as inhibitors of viral replication
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) * 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
WO2009070692A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
EP2226315A4 (en) 2007-12-28 2012-01-25 Carna Biosciences Inc 2-AMINOQUINAZOLINE DERIVATIVE
JP5490778B2 (ja) 2008-03-20 2014-05-14 エナンタ ファーマシューティカルズ インコーポレイテッド C型肝炎ウイルス阻害剤としてのフッ素化大環状化合物
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2300491B1 (en) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010068760A2 (en) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2898529C (en) * 2009-02-27 2017-10-17 Peter Jozef Maria Van Remoortere Amorphous sodium salt of tmc435 inhibitor of hcv
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US20120129875A1 (en) * 2009-05-29 2012-05-24 Syngenta Crop Protection, Llc Substituted quinazolines as fungicides
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
MX2013007698A (es) 2010-12-30 2013-08-15 Abbvie Inc Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina.
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104203940B (zh) 2011-12-28 2017-01-18 爱尔兰詹森科学公司 作为hcv抑制剂的杂双环衍生物
CA2886973C (en) * 2012-10-15 2017-08-15 Albemarle Corporation Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds
RS55592B1 (sr) 2012-10-19 2017-06-30 Bristol Myers Squibb Co 9-metil supstituisani heksadekahidrociklopropa(e)pirolo(1,2-a)(1,4)diazaciklopentadecinil karbamat derivati kao nestrukturalni 3 (ns3) proteazni inhibitori za lečenje infekcijavirusom hepatitisa c
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
JP2005535574A (ja) 2002-04-11 2005-11-24 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にhcvns3−ns4aプロテアーゼのインヒビター
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
WO2004072243A2 (en) * 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
US20040180815A1 (en) * 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
ES2386161T3 (es) * 2003-04-16 2012-08-10 Bristol-Myers Squibb Company Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
US7642235B2 (en) * 2003-09-22 2010-01-05 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
ATE461209T1 (de) * 2004-01-30 2010-04-15 Medivir Ab Hcv ns-3 serine protease inhibitoren
AR054882A1 (es) * 2005-07-29 2007-07-25 Tibotec Pharm Ltd Inhibidores macrociclicos del virus de la hepatitis c
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
BRPI0613933A2 (pt) * 2005-07-29 2011-02-22 Medivir Ab inibidores macrocìlicos do vìrus da hepatite c
AR055105A1 (es) * 2005-07-29 2007-08-08 Tibotec Pharm Ltd Inhibidores macrociclicos del virus de la hepatitis c

Also Published As

Publication number Publication date
ME01454B (me) 2014-04-20
IL188320A (en) 2014-07-31
CY1110008T1 (el) 2015-01-14
HK1116488A1 (en) 2008-12-24
EA200800482A1 (ru) 2008-06-30
EP1912981A2 (en) 2008-04-23
ATE455775T1 (de) 2010-02-15
AU2006274866B2 (en) 2012-04-12
CA2617103C (en) 2015-01-06
NO20081075L (no) 2008-04-25
JP2009502890A (ja) 2009-01-29
US20090118312A1 (en) 2009-05-07
UY29704A1 (es) 2007-05-31
PT1912981E (pt) 2010-04-16
KR101083631B1 (ko) 2011-11-16
TWI387597B (zh) 2013-03-01
US7659245B2 (en) 2010-02-09
WO2007014927A3 (en) 2007-11-29
NZ564540A (en) 2010-03-26
PE20070343A1 (es) 2007-05-12
SV2008002641A (es) 2008-07-23
IL188320A0 (en) 2008-04-13
DE602006011905D1 (de) 2010-03-11
DK1912981T3 (da) 2010-05-25
AU2006274866A1 (en) 2007-02-08
SI1912981T1 (sl) 2010-05-31
CA2617103A1 (en) 2007-02-08
WO2007014927A2 (en) 2007-02-08
MY151026A (en) 2014-03-31
GT200600343A (es) 2007-08-06
HRP20100209T1 (hr) 2010-05-31
KR20080033475A (ko) 2008-04-16
EP1912981B1 (en) 2010-01-20
BRPI0614153A2 (pt) 2011-03-15
EA014188B1 (ru) 2010-10-29
AP2585A (en) 2013-02-04
TW200745116A (en) 2007-12-16
JP5230418B2 (ja) 2013-07-10
AR057702A1 (es) 2007-12-12
PL1912981T3 (pl) 2010-07-30
ES2339702T3 (es) 2010-05-24

Similar Documents

Publication Publication Date Title
RS51227B (sr) Makrociklički inhibitori virusa hepatitisa c
RS53512B1 (en) SUBSTITUTED IMIDASOLS AND THEIR USE AS PESTICIDES
NO20064669L (no) Dipeptidylpeptidaseinhibitorer
ATE544791T1 (de) Copolymer und ophthalmologische zusammensetzung
RS52694B (sr) Pirimidinski derivati za tretman astme, hobp, alergijskog rinitisa, alergijskog konjunktivitisa, atopičnog dermatitisa, raka, hepatitisa b, hepatitisa c, hiv-a, hpv-a, bakterijskih infekcija i dermatoze
MX2016007125A (es) Una composicion de revestimiento.
MX2010004623A (es) Compuestos heterociclicos antiviricos.
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
NO20084701L (no) Ny heterocyklisk forbindelse eller salt eller intermediat derav
WO2007016392A3 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
WO2007070600A3 (en) N-(5-membered heteroaromatic ring)-amido anti-viral compounds
MY160443A (en) Nitrogen-containing heterocyclic compound and agricultural fungicide
RS51243B (sr) Inhibitori ns-3 serina hcv proteaze
MX2009006880A (es) Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
RS51136B (sr) Supstituisani pirolopiridini, kompozicije koje ih sadrže, postupak za njihovo dobijanje i upotreba
ATE338461T1 (de) Pyrazolpyrimidinfungizide
WO2009057811A3 (en) Heterocyclic compound and pharmaceutical composition thereof
TW200636390A (en) Photosensitive resin composition and color filter using the same
CO6170367A2 (es) Una resina de intercambio ionico y un proceso para su uso
MX2012006513A (es) Compuestos heterociclicos antivirales.
BRPI0601766A (pt) composições contendo aminas e seu uso
ATE519818T1 (de) Reversibel thermochrome zusammensetzung
CR11084A (es) Compuesto biciclico y uso farmaceutico del mismo
DK2125807T3 (da) Imidazo[1,2-A]pyrrolo[3,2-C]pyridin-forbindelser, der er egnede som pestivirusinhibitorer